In a paper published in Brain (available online ahead of print here), we specifically studied a series of demented patients with a clinical diagnosis of Alzheimer’s disease but who had a negative beta-amyloid PET scan. The paper includes cross sectional and longitudinal clinical data, as well as neuroimaging data from structural MRI and FDG-PET.
This publication, led by Gael Chetelat’s group in Caen, France, is the result of a great collaboration with three other world-famous groups:
– The group of Gil Rabinovici at UCSF (+Bill Jagust at UC Berkeley)
– The group led by Chris Rowe and Victor Villemagne in Melbourne
– The group led by Philip Scheltens in Amsterdam
Chételat G, Ossenkoppele R, Villemagne VL, Perrotin A, Landeau B, Mezenge F, Jagust WJ, Dore V, Miller BL, Egret S, Seeley WS, van der WM, La Joie R, Ames D, van Berckel BNM, Scheltens P, Barkhof F, Rowe CC, Masters CL, de La Sayette V, Bouwman F, Rabinovici GD (in press). Atrophy, hypometabolism and clinical trajectories in amyloid-negative Alzheimer’s disease patients. Brain
Like this:
Like Loading...
Related
About Renaud La Joie
PhD in neuroscience/neuropsychology.
I am interested in age-related neurodegenerative diseases including Alzheimer’s disease & related disorders.
My research involves multimodal neuroimaging and neuropsychological tools, as complementary approaches are required to better characterize - and hopefully understand - these disorders. From a more fundamental perspective, studying the diseased brain will also contribute to further our knowledge on the neural basis of cognitive functions in the normal brain.
Renaud La Joie 